

Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study

Antony Loebel, M.D.

Josephine Cucchiaro, Ph.D.

Robert Silva, Ph.D.

Hans Kroger, M.P.H., M.S.

Jay Hsu, Ph.D.

Kaushik Sarma, M.D.

Gary Sachs, M.D.

Objective: The authors evaluated the efficacy and safety of lurasidone in the treatment of patients with major depressive episodes associated with bipolar I disorder.

Method: Patients were randomly assigned to receive double-blind treatment with lurasidone (20–60 mg/day [N=166] or 80–120 mg/day [N=169]) or placebo (N=170) for 6 weeks. Primary and key secondary endpoints were change from baseline to week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) and depression severity score on the Clinical Global Impressions scale for use in bipolar illness (CGI-BP), respectively.

Results: Lurasidone treatment significantly reduced mean MADRS total scores at week 6 for both the 20–60 mg/day group (–15.4; effect size=0.51) and the 80–120 mg/day group (–15.4; effect size=0.51) compared with placebo (–10.7). Similarly, lurasidone treatment resulted in significantly greater endpoint reduction in CGI-BP depression severity scores

for both the 20–60 mg/day group (–1.8; effect size=0.61) and the 80–120 mg/day group (–1.7; effect size=0.50) compared with placebo (–1.1). Both lurasidone groups also experienced significant improvements compared with placebo in anxiety symptoms and in patient-reported measures of quality of life and functional impairment. Discontinuation rates due to adverse events were similar in the 20–60 mg/day (6.6%), 80–120 mg/day (5.9%), and placebo (6.5%) groups. The most frequent adverse events associated with lurasidone were nausea, headache, akathisia, and somnolence. Minimal changes in weight, lipids, and measures of glycemic control were observed with lurasidone.

Conclusion: Monotherapy with lurasidone in the dosage range of 20–120 mg/day significantly reduced depressive symptoms in patients with bipolar I depression. Lurasidone was well tolerated, with few changes in weight or metabolic parameters.

(*Am J Psychiatry* 2014; 171:160–168)

Bipolar I disorder is a serious, often disabling illness with an estimated prevalence of approximately 1%, an early age at onset (mean=18 years), and a chronic and recurrent course (1, 2). Over the course of the illness, major depressive episodes predominate (3, 4) and are associated with marked impairment in social and occupational functioning (5), a heavy burden of both direct and indirect health care costs (4–6), and an increased risk of suicide (7, 8). The World Health Organization (WHO) ranks bipolar disorder among the top 20 causes of disability worldwide (9).

The chronicity and impact of depressive episodes associated with bipolar disorder, while greater than those of manic episodes, are not as well studied, and fewer treatment options are available (10, 11). Currently, only two medications are approved in the United States, and in some other countries, for the treatment of acute bipolar depression: a combination of olanzapine-fluoxetine has demonstrated superiority to both olanzapine and placebo (12), and quetiapine has demonstrated efficacy in both immediate

and extended-release formulations (13). Olanzapine has also demonstrated efficacy in bipolar I depression (12, 14) and is approved for this use in Japan. The atypical agents aripiprazole and ziprasidone did not differentiate from placebo in randomized bipolar I depression trials (15–17).

Treatment with mood-stabilizing agents frequently provides insufficient antidepressant efficacy (11, 18), and there is limited evidence supporting the use of standard tricyclic or serotonergic antidepressants for the treatment of bipolar depression (10). Therefore, there is a substantial lack of effective and well-tolerated therapies for bipolar depression, underscoring the pressing need to identify proven new treatments for this condition.

Lurasidone is an atypical antipsychotic with high affinity for D₂, 5-HT_{2A}, and 5-HT₇ receptors (antagonist), moderate affinity for 5-HT_{1A} receptors (partial agonist), and no appreciable affinity for H₁ and M₁ receptors (19, 20). Antagonist activity at 5-HT₇ receptors has been reported to be associated with antidepressant effects in animal

This article is featured in this month's AJP **Audio**, is an article that provides **Clinical Guidance** (p. A18), and is discussed in an **Editorial** by Dr. Belmaker (p. 131)

behavioral models of depression (21). Lurasidone has demonstrated significant improvement in both acute and chronic animal models of depression (22). Furthermore, the antidepressant effect of lurasidone in these preclinical behavioral models was absent in 5-HT₇ knockout mice, indicating that this effect required the presence of functional 5-HT₇ receptors (22). Therefore we hypothesized that the activity of lurasidone at 5-HT₇ and other 5-HT receptor subtypes make it a promising candidate as an antidepressant in patients with bipolar depression.

Lurasidone has been approved by the U.S. Food and Drug Administration for the treatment of bipolar I depression, both as monotherapy and as adjunctive therapy with lithium or valproate (20). The primary objective of this placebo-controlled phase 3 study was to evaluate the efficacy of lurasidone monotherapy for the treatment of bipolar I depression.

Method

Subjects

This international study enrolled outpatients 18–75 years of age diagnosed with bipolar I disorder who were experiencing a major depressive episode (DSM-IV-TR criteria, ≥ 4 weeks and < 12 months in duration), with or without rapid cycling, without psychotic features, and with a history of at least one lifetime bipolar manic or mixed manic episode. Diagnosis was confirmed by the Mini-International Neuropsychiatric Interview (23) and the Bipolarity Index (24). A Montgomery-Åsberg Depression Rating Scale (MADRS [25]) score ≥ 20 and a Young Mania Rating Scale (YMRS) score ≤ 12 were required at both screening and baseline.

Patients were excluded if they demonstrated a decrease of $\geq 25\%$ in MADRS total score between screening and baseline; scored ≥ 4 on MADRS item 10 (suicidal thoughts) at screening or baseline; had a history of nonresponse to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current depressive episode, or demonstrated imminent risk of suicide or injury to self, others, or property.

The study was approved by an institutional review board at each investigational site and was conducted in accordance with the International Conference on Harmonisation Good Clinical Practices guidelines and with the ethical principles of the Declaration of Helsinki. All patients who entered the study reviewed and signed an informed consent document explaining study procedures and potential risks before study entry. An independent data and safety monitoring board reviewed and monitored subject data throughout the study.

Study Design

This randomized, double-blind, placebo-controlled, fixed-flexible dose, parallel-group monotherapy study of lurasidone compared with placebo was conducted between April 2009 and February 2012. A total of 505 patients underwent random assignment at sites in the United States (205 patients from 24 sites), India (76 patients from nine sites), Ukraine (52 patients from five sites), Czech Republic (55 patients from four sites), South Africa (57 patients from four sites), Russia (31 patients from four sites), Romania (16 patients from four sites), and France (13 patients from one site). Following a washout period of at least 3 days, patients were randomly assigned in a 1:1:1 ratio via an interactive voice response system to receive 6 weeks of treatment with lurasidone, at flexible daily doses of either 20–60 mg or 80–120 mg, or 6 weeks of placebo. Study medication was provided in blister

packs as either lurasidone 20 mg or 40 mg, or identically matched placebo tablets, and was taken once daily in the evening, with a meal or within 30 minutes after eating.

Patients assigned to receive lurasidone 20–60 mg/day were treated with 20 mg/day for days 1–7. Patients assigned to the lurasidone 80–120 mg/day arm received a fixed titration of lurasidone as follows: 20 mg/day for days 1–2, 40 mg/day for days 3–4, 60 mg/day for days 5–6 and 80 mg/day on day 7. In both treatment arms, lurasidone dosing adjustments within the assigned dosing range were permitted after 7 days to optimize efficacy and tolerability. Lurasidone (or placebo) was taken once daily in the evening, with a meal or within 30 minutes after eating.

Concomitant Medications

Treatment with anticholinergic agents, propranolol, or amantadine, was permitted as needed (but not prophylactically) for movement disorders. Lorazepam, temazepam, or zolpidem (or their equivalent) were permitted during screening and for weeks 1 to 3, as needed for anxiety or insomnia, but not prophylactically, and not within 8 hours of any psychiatric assessment.

Efficacy Assessments

Efficacy assessments were obtained at baseline and weekly intervals. The primary efficacy endpoint was the mean change from baseline to week 6 in MADRS total score. At each study visit, a qualified site-based rater conducted the MADRS assessment; a second MADRS assessment was administered and scored by computer as part of a quality control process (Concordant Rater Systems, Boston, MA). The key secondary efficacy endpoint was the mean change from baseline to week 6 in depression severity score on the Clinical Global Impressions scale for use in bipolar illness (CGI-BP [26]).

Additional secondary efficacy assessments included the 16-item Quick Inventory of Depressive Symptomatology (27), the Hamilton Anxiety Rating Scale (HAM-A [28]), the Sheehan Disability Scale (29), and the Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form (30).


Safety and Tolerability Evaluations

Safety and tolerability were assessed by the incidence and severity of adverse events during the study. Movement disorders were assessed by the Simpson-Angus Scale, the Abnormal Involuntary Movement Scale, and the Barnes Akathisia Rating Scale. Additional safety evaluations included vital signs, laboratory tests, 12-lead ECG, and physical examination. Treatment-emergent mania was defined a priori as a Young Mania Rating Scale (YMRS [31]) score ≥ 16 on any two consecutive visits, or at the final assessment, or an adverse event of mania or hypomania. Suicidal ideation and behavior were assessed using the Columbia Suicide Severity Rating Scale (32).

Statistical Analysis

The intent-to-treat population consisted of randomly assigned subjects who received at least one dose of study medication and had at least one postbaseline efficacy assessment. The primary (MADRS) and key secondary (CGI-BP depression severity) efficacy endpoints were assessed using a mixed model for repeated-measures analysis including treatment, visit, pooled center, baseline score, and a treatment-by-visit interaction term, using an unstructured covariance matrix for within-subject correlation. The Hommel-based tree gatekeeping procedure was applied to control the family-wise type I error rate at 5% by taking into account the primary and key secondary efficacy variables and multiple dose comparisons of lurasidone versus placebo. There was no multiplicity adjustment for the secondary efficacy analyses or safety analyses.

Change from baseline in secondary efficacy measures was evaluated using an analysis of covariance (ANCOVA) model with fixed effects for treatment, pooled center, and baseline score as a covariate. Core depressive symptoms were evaluated using the

FIGURE 1. Patient Disposition in a Double-Blind, Randomized, Placebo-Controlled Trial of Lurasidone for Bipolar I Depression

MADRS-6 subscale (33). The proportions of responders ($\geq 50\%$ reduction from baseline in MADRS total) and remitters (MADRS total ≤ 12) were compared between the lurasidone and placebo treatment groups using logistic regression. Cohen's *d* effect sizes were calculated for the primary outcome as the difference in the change score divided by the pooled standard deviation. The number needed to treat to attain an additional responder was derived for the lurasidone group as follows: number needed to treat = $1/(\text{lurasidone response rate} - \text{placebo response rate})$.

The safety population included all subjects who were randomly assigned and received at least one dose of study medication. Descriptive statistics were used for safety variables including adverse events, vital signs, and laboratory results. In addition, a nonparametric rank ANCOVA was used to analyze weight and laboratory parameters. Change from baseline to last observation carried forward endpoint in the Simpson-Angus Scale, the Abnormal Involuntary Movement Scale, and the Barnes Akathisia Rating Scale scores were analyzed by using an analysis of covariance (ANCOVA) model with fixed effects for treatment, pooled center, and baseline score as a covariate.

Sample size was determined by using an SAS simulation macro (34) and was powered at 82.4% to reject both null hypotheses of no difference in MADRS between placebo and lurasidone dosage groups (3.5-point difference; pooled standard deviation of 9), and was powered at 96% to reject at least one null hypothesis of no difference from placebo for the lurasidone dosage groups. The estimated sample size of $N=168$ per treatment arm (total $N=504$) included an additional eight patients (5%) per arm based on expected early attrition (patients randomly assigned but without any postbaseline efficacy measures).

Results

Patients and Disposition

A total of 818 patients were screened, of whom 505 (61.7%) were randomly assigned to 6 weeks of double-blind

treatment (Figure 1); 499 received at least one dose of study medication (safety population), and 485 had at least one postbaseline efficacy assessment (intent-to-treat population). Baseline demographic and clinical characteristics were similar for the two treatment groups (Table 1). Study completion rates were similar for the lurasidone 20–60 mg (74%), lurasidone 80–120 mg (73%), and placebo (75%) groups (Figure 1).

The mean daily dose of lurasidone during the study was 31.8 mg in the 20–60 mg group and 82.0 mg in the 80–120 mg group. For the 20–60 mg group (after 20 mg/day for 7 days), 66.7% of patients increased to a dosage of 40 mg/day, and 34.0% increased to a dosage of 60 mg/day at some point during the remaining 5 weeks of study treatment. For the 80–120 mg group (after fixed dose titration from 20 mg/day to 80 mg/day at day 7), 62.0% of patients increased to a dosage of 100 mg/day, and 26.6% increased to a dosage of 120 mg/day at some point during the remaining 5 weeks of study treatment.

As-needed treatment with lorazepam was reported by 12% of patients in the lurasidone 20–60 mg group, 13% of patients in the lurasidone 80–120 mg group, and 19% of patients in the placebo group. As-needed treatment with zolpidem was reported by 13% of patients in the lurasidone 20–60 mg group, 8% of patients in the lurasidone 80–120 mg group, and 8% of patients in the placebo group.

Efficacy

The least squares mean change from baseline to week 6 in MADRS total score (the primary endpoint) was significantly greater than seen with placebo (-10.7) for

TABLE 1. Demographic and Clinical Characteristics at Baseline (intent-to-treat population) of Patients in a Double-Blind, Randomized, Placebo-Controlled Trial of Lurasidone for Bipolar I Depression

Characteristic	Group					
	Lurasidone, 20–60 mg/day (N=161)		Lurasidone, 80–120 mg/day (N=162)		Placebo (N=162)	
	N	%	N	%	N	%
Female	91	57	98	60	87	54
Race						
White	107	66	106	65	107	66
Black	21	13	25	15	21	13
Asian	23	14	23	14	28	17
Other	10	6	8	5	6	4
Hispanic/Latino ethnicity	8	5	6	4	8	5
≥4 previous hospitalizations	20	13	21	13	24	15
	Mean	SD	Mean	SD	Mean	SD
Age (years)	41.3	12.3	42.0	12.4	41.2	12.5
Age at onset of illness (years)	27.9	11.9	27.6	10.8	27.4	10.8
Assessment scores						
MADRS	30.3	5.0	30.6	4.9	30.5	5.0
CGI-BP depression severity	4.5	0.6	4.6	0.6	4.5	0.6
Hamilton Anxiety Rating Scale	16.3	6.7	15.6	5.6	16.2	6.4
Young Mania Rating Scale	4.4	2.7	4.1	2.5	4.3	3.0
Quick Inventory of Depressive Symptomatology	14.1	3.6	14.6	3.4	14.7	3.4
Quality of Life, Enjoyment, and Satisfaction Questionnaire	33.8	13.7	33.5	13.0	34.2	13.5
Sheehan Disability Scale	19.7	4.8	19.8	5.6	19.8	5.0

the lurasidone 20–60 mg group (-15.4 ; $p<0.001$ [effect size=0.51]) and the lurasidone 80–120 mg group (-15.4 ; $p<0.001$ [effect size=0.51]) (Figure 2A). The least squares mean change from baseline to week 6 in CGI-BP depression severity score (key secondary endpoint) was significantly greater than seen with placebo (-1.1) for the lurasidone 20–60 mg group (-1.8 ; $p<0.001$ [effect size=0.61]) and the lurasidone 80–120 mg group (-1.7 ; $p<0.001$ [effect size=0.50]) (Figure 2B). For both dosages of lurasidone, superiority compared with placebo on the MADRS was observed starting at week 2 and was maintained at all subsequent study visits. Superiority compared with placebo on the CGI-BP depression severity score was observed starting at week 1 for the lurasidone 80–120 mg group and starting at week 2 for the lurasidone 20–60 mg group and was maintained at all subsequent study visits.

There was a statistically significant reduction from baseline to week 6 in core depressive symptoms (MADRS-6 subscale score) for the lurasidone 20–60 mg group (-10.4 ; $p<0.001$) and the lurasidone 80–120 mg group (-10.4 ; $p<0.001$) relative to the placebo group (-6.9). Lurasidone was associated with significantly greater improvement than placebo on seven of the 10 MADRS items in both the 20–60 mg and 80–120 mg groups (Figure 2C).

A significantly greater proportion of subjects met a priori response criteria after 6 weeks of treatment with lurasidone 20–60 mg (53%; $p<0.001$ [number needed to treat=5]) and lurasidone 80–120 mg (51%; $p<0.001$ [number needed to treat=5]) compared with placebo (30%). Median time to

response was shorter in the lurasidone 20–60 mg group (34 days) and the 80–120 mg group (30 days) compared with the placebo group (42 days; log-rank $p<0.01$ for both comparisons).

The proportion of subjects achieving remission at endpoint was significantly greater in the lurasidone 20–60 mg group (42%; $p=0.001$ [number needed to treat=6]) and the lurasidone 80–120 mg group (40%; $p=0.004$ [number needed to treat=7]) compared with the placebo group (25%).


No significant treatment interactions by gender, age, race, or ethnicity were observed for either the MADRS total score or the CGI-BP depression severity score, based on ANCOVA analyses.

Treatment with both dosages of lurasidone was associated with significant improvement compared with placebo in anxiety symptoms, as measured by the clinician-rated Hamilton anxiety scale, the patient-rated Quick Inventory of Depressive Symptomatology, the Quality of Life, Enjoyment, and Satisfaction Questionnaire, and the Sheehan Disability Scale (Figure 3).

Safety

Overall, adverse events reported with an incidence $\geq 5\%$ in at least one of the groups are listed in Table 2. The majority of adverse events were considered mild or moderate, with $<10\%$ rated as “severe” in the lurasidone 20–60 mg (9.8%) and 80–120 mg (8.4%) groups or the placebo group (6.0%). The incidence of serious treatment-related adverse events was low and similar in the lurasidone 20–60 mg group ($N=2$), the 80–120 mg

FIGURE 2. Change From Baseline in Key Efficacy Measures




^a Mean scores at baseline were 30.3 (SD=5.0), 30.6 (SD=4.9), and 30.5 (SD=5.0) for the lurasidone 20–60 mg, lurasidone 80–120 mg, and placebo groups, respectively.

^b Mean scores at baseline were 4.52 (SD=0.62), 4.55 (SD=0.64), and 4.48 (SD=0.61) for the lurasidone 20–60 mg, lurasidone 80–120 mg, and placebo groups, respectively.

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

group (N=1), and the placebo group (none). No deaths occurred during the study. The proportion of patients who discontinued due to adverse events was similar in the lurasidone 20–60 mg group (6.6%), the 80–120 mg group (5.9%), and the placebo group (6.5%; Figure 1).

Treatment-emergent mania occurred in 3.7% of patients in the lurasidone 20–60 mg group, 1.9% in the lurasidone 80–120 mg group, and 1.9% in the placebo group. Mean YMRS scores showed a similar endpoint reduction in the lurasidone 20–60 mg group (–1.1), the 80–120 mg group (–0.7), and in the placebo group (–0.9).

FIGURE 3. Baseline-to-Endpoint Change Scores on Additional Secondary Efficacy Measures (intent-to-treat population)^a

^a LOCF=last observation carried forward.

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$

The proportion of patients with at least one instance of treatment-emergent suicidal ideation, per the Columbia Suicide Severity Rating Scale, was 13.7% in the lurasidone 20–60 mg group, 14.8% in the lurasidone 80–120 mg group, and 13.6% in the placebo group. There was no occurrence of suicidal behavior or completed suicide during the study.

The incidence of extrapyramidal symptom-related adverse events was less than 10% in both lurasidone groups, with a modest dose-related increase in incidence (Table 2). The proportion of patients who received treatment with anticholinergic medication for acute extrapyramidal symptoms

was 3.7% in the lurasidone 20–60 mg group, 4.9% in the lurasidone 80–120 mg group, and 1.9% in the placebo group. Least squares mean changes from baseline to endpoint (lurasidone 20–60 mg and 80–120 mg versus placebo) were small for the Barnes Akathisia Scale (0.0 and 0.2 versus -0.1), and for the Simpson Angus Scale (0.02 and 0.02 versus 0.00). There were no significant changes from baseline to endpoint in the Abnormal Involuntary Movement Scale total score in any treatment group with no statistically significant differences between the lurasidone treatment groups and the placebo group.

TABLE 2. Adverse Events (incidence $\geq 5\%$, with incidence greater for the lurasidone group versus placebo; safety population)

Event	Group					
	Lurasidone, 20–60 mg/day (N=164)		Lurasidone, 80–120 mg/day (N=167)		Placebo (N=168)	
	N	%	N	%	N	%
At least one event	101	61.6	108	64.7	96	57.1
Nausea	17	10.4	29	17.4	13	7.7
Headache	23	14.0	15	9.0	20	11.9
Akathisia	13	7.9	18	10.8	4	2.4
Somnolence	7	4.3	11	6.6	7	4.2
Sedation	5	3.0	12	7.2	3	1.8
Dry mouth	10	6.1	6	3.6	7	4.2
Vomiting	4	2.4	10	6.0	3	1.8
Extrapyramidal events ^a	8	4.9	15	9.0	4	2.4

^a Drooling, dystonia, muscle rigidity, oromandibular dystonia, parkinsonism, torticollis, and tremor.

TABLE 3. Baseline to Endpoint Change in Weight and Laboratory Parameters (last observation carried forward)^a

Measure	Group								
	Lurasidone, 20–60 mg/day (N=164)			Lurasidone, 80–120 mg/day (N=167)			Placebo (N=168)		
	Mean	SD	Median	Mean	SD	Median	Mean	SD	Median
Weight (kg)	0.6	1.9	0.4	0.0	2.1	0.0	0.0	1.8	0.0
Total cholesterol (mg/dl)	1.2	25.4	0.0	−4.6	30.2	−3.0	−3.2	27.1	−3.0
LDL cholesterol (mg/dl)	−1.2	12.2	0.0	−4.1	25.8	−4.0	−3.5	23.9	−2.0
Triglycerides (mg/dl)	5.6	65.4	3.0	0.4	65.7	−2.0	6.0	55.7	8.0
Glucose (mg/dl)	−0.8	14.9	−1.0	1.8	17.6	0.0	1.8	18.4	0.5
HbA1c (%)	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.2	0.0
Insulin (mU/liter)	2.8	24.8	0.7	4.3	21.2	0.8	2.9	19.9	0.2
Prolactin (ng/ml)	5.3	18.5	1.7	5.3	18.8	3.5	−2.0	28.2	0.3
Men	2.6	9.3	1.2	4.8	14.1	1.9	0.9	14.9	0.4
Women	7.5	23.3	1.8	5.6	21.3	5.3	−4.2	35.3	0.0

^a Both confirmed and nonconfirmed fasting values are presented for metabolic parameters.

There were no notable differences in laboratory measures, vital signs, or ECG assessments between treatment groups. Mean endpoint change in weight was not different for the lurasidone 20–60 mg group (+0.6 kg), the lurasidone 80–120 mg group (0.0 kg), and the placebo group (0.0 kg). The proportion of subjects with $\geq 7\%$ increase in weight at endpoint was 4.2% in the lurasidone 20–60 mg group, 0.7% in the 80–120 mg group, and 0.7% in the placebo group. Mean change in waist circumference was also similar in the combined lurasidone group compared with the placebo group (0.1 cm versus −0.3 cm).

There were no clinically meaningful differences in the effect of treatment on metabolic parameters between the lurasidone groups and the placebo group (Table 3). Median endpoint change in prolactin for lurasidone 20–60 mg and 80–120 mg, respectively, versus placebo was higher in female than in male subjects. The mean endpoint change in QTcF interval from baseline to endpoint was 0.5 ms in the lurasidone 20–60 mg group, −1.0 ms in the lurasidone 80–120 mg group, and −1.7 ms in the placebo group. No patient in either lurasidone group had a postbaseline change in QTcF > 60 ms, and no patient in either lurasidone group had a QTcF > 500 ms.

Discussion

In this multicenter, placebo-controlled, short-term study, monotherapy with lurasidone, in the fixed-flexible dosage ranges of 20–60 mg/day and 80–120 mg/day, significantly improved depressive symptoms in patients with bipolar depression. For both daily dose ranges, lurasidone was associated with significantly greater improvement in the MADRS starting at week 2 and at all subsequent visits through the week 6 study endpoint. These findings were supported by significantly greater improvement in the key secondary outcome, CGI-BP depression severity, which assessed the global severity of depressive symptoms, and by significant improvement in the core symptoms of depression as assessed by the MADRS-6 subscale. In addition, treatment with both dosage ranges of lurasidone was associated with significant improvement in anxiety symptoms, functional impairment, and quality of life. There were no significant treatment interactions by gender, age, race, or ethnicity.

A fixed-flexible dose design was selected to allow some of the advantages of flexibility in dosing while still permitting assessment of dose-response relationships

(35). The present study found comparable efficacy for the 20–60 mg/day and 80–120 mg/day dosage ranges of lurasidone, suggesting that treatment should be started at 20 mg/day and increased as needed over the 20–120 mg/day range (20).

The magnitude of improvement in MADRS scores at week 6 in the lurasidone treatment groups was comparable to results from previous placebo-controlled monotherapy trials with atypical antipsychotics, as summarized in a recent meta-analysis (36). The lurasidone versus placebo difference in MADRS scores was 4.6 for both dosage ranges in the current study, while the weighted mean drug versus placebo difference in MADRS scores in the meta-analysis ranged from 1.1 for aripiprazole and 3.1 for olanzapine to 4.6 for quetiapine 600 mg (immediate-release only) and 4.8 for quetiapine 300 mg (extended- and immediate-release [37]). Since this meta-analysis was completed, an additional large placebo-controlled study of olanzapine has been reported, with a mean difference (versus placebo) on the MADRS of 2.2 (14).

Lurasidone has been extensively studied for the short- and long-term treatment of schizophrenia (20), and the present study revealed no new safety concerns or risks. Consistent with previous studies, treatment with lurasidone was associated with a small dose-related effect on prolactin, and minimal changes in weight, lipids, and measures of glycemic control. Lurasidone has been reported to have appreciably fewer weight and metabolic effects than other atypical antipsychotic agents (37). The diagnosis of bipolar disorder is associated with high rates of metabolic syndrome (38) and a significant increase in the risk of cardiovascular disease (39). The metabolic profile of lurasidone reported here is consistent with prior schizophrenia studies and suggests that it may be associated with low cardiometabolic risk in this vulnerable clinical population.

No difference was observed between the lurasidone groups and placebo in the incidence of either treatment-emergent mania or suicidal ideation. No suicidal behavior occurred. Mania symptom severity was low at baseline as measured by the YMRS and showed small reductions over the course of the study in all treatment groups.

Treatment with both dosage ranges of lurasidone was well tolerated, with discontinuation rates due to adverse events that were low and similar to placebo. There was a modest, dose-related increase in the frequency of nausea, sedation, vomiting, and extrapyramidal symptoms for the 80–120 mg/day range versus the 20–60 mg/day range. Adverse events were typically mild to moderate in intensity, with <10% of events in the lurasidone groups rated as “severe,” only slightly higher than the incidence reported with placebo.

Several study limitations should be noted. Since only patients with bipolar I depression were enrolled, the extent to which these findings can be generalized to patients with bipolar II depression is not clear. Study entry criteria that

excluded patients with serious psychiatric or medical comorbidity, and active suicidal ideation or behavior, also may have reduced the generalizability of the results. In this study, the suicidal thoughts item of the MADRS did not separate from placebo, perhaps in part because of low baseline severity. Further investigation is needed to evaluate the maintenance efficacy and longer-term safety of lurasidone in patients with bipolar disorder.

In conclusion, the results of this study found lurasidone, in the dosage range of 20–120 mg, to be an efficacious treatment for bipolar depression, with improvements observed in depressive and anxiety symptoms, functional impairment, and quality of life. Treatment with lurasidone was well tolerated, with minimal effect on weight, lipid parameters, and measures of glycemic control. This clinical profile suggests that lurasidone may be a valuable addition to the therapeutic armamentarium for the treatment of patients with bipolar depression.

Presented in part at the 165th annual meeting of the American Psychiatric Association, Philadelphia, May 5–9, 2012; the 51st annual meeting of the American College of Neuropsychopharmacology, Hollywood, Fla., December 2–6, 2012; and the 10th International Conference on Bipolar Disorders, Miami Beach, June 13–16, 2013. Received July 27, 2013; revision received Sept. 9, 2013; accepted Sept. 10, 2013 (doi: 10.1176/appi.ajp.2013.13070984). From Sunovion Pharmaceuticals, Inc., Fort Lee, N.J., and Marlborough, Mass.; and the Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston. Address correspondence to Dr. Loebel (Antony.Loebel@sunovion.com).

Dr. Sachs has been a consultant for Sunovion, Otsuka, Johnson & Johnson, and Grunenthal, has stock/other financial relationship with Collaborative Care Initiative, and is an employee of Bracket. Drs. Loebel, Cucchiaro, Silva, Kroger, Hsu, and Sarma are full-time employees of Sunovion Pharmaceuticals, Inc.

This study was sponsored by Sunovion Pharmaceuticals, Inc.

The authors thank the participants of this study, as well as the members of the Lurasidone Bipolar Disorder Study Group (*Czech Republic*: Drs. J. Drahozal, E. Herman, M. Klabusayova, and Z. Solle; *France*: Dr. M. Zins Ritter; *India*: Drs. M. Chudgar, H. Gandhi, M. Gowda, V. Indla, U. Nagapurkar, J. Trivedi, P. Thatikonda, M. Vaishnav, and R. Yadav; *Romania*: Drs. M.G. Badescu, D. Cozman, G. Oros, and D. Vasile; *Russia*: Drs. M. Ivanov, V. Kozlovsky, V. Tochilov, and V. Vid; *South Africa*: Drs. K. Botha, G. Jordaan, L. Nel, J. Schronen; *Ukraine*: Drs. V. Abramov, V. Bitensky, S. Rymsha, A. Skrypnikov, and V. Verbenko; *United States*: Drs. S. Aaronson, M. Alam, S. Atkinson, P. Bhatia, R. Brenner, J. Calabrese, A. Cutler, G. Dempsey, D. Garcia, E. Gfeller, H. Hassman, R. Knapp, R. Manning, J. Miller, N. Rosenthal, R. Hidalgo, T. Tran-Johnson, N. Vatakis, D. Walling, R. Weisler, K. Yadalam, M. Allen, J. Kunovac, and S. Potkin).

Clinicaltrials.gov identifier: NCT00868699

References

1. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. *Arch Gen Psychiatry* 2007; 64:543–552
2. Treuer T, Tohen M: Predicting the course and outcome of bipolar disorder: a review. *Eur Psychiatry* 2010; 25:328–333
3. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB: The long-term natural history of the weekly symptomatic status of bipolar I disorder. *Arch Gen Psychiatry* 2002; 59:530–537

4. Calabrese JR, Hirschfeld RM, Frye MA, Reed ML: Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a US community-based sample. *J Clin Psychiatry* 2004; 65:1499–1504
5. Fagiolini A, Forgione R, Maccari M, Cuomo A, Morana B, Dell'Osso MC, Pellegrini F, Rossi A: Prevalence, chronicity, burden and borders of bipolar disorder. *J Affect Disord* 2013; 148:161–169
6. Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. *J Affect Disord* (Epub ahead of print: Nov 7, 2012; doi: 10.1016/j.jad.2012.10.002
7. Jamison KR: Suicide and bipolar disorder. *J Clin Psychiatry* 2000; 61(Suppl 9):47–51
8. Leverich GS, Altshuler LL, Frye MA, Suppes T, Keck PE Jr, McElroy SL, Denicoff KD, Obrocea G, Nolen WA, Kupka R, Walden J, Grunze H, Perez S, Luckenbaugh DA, Post RM: Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. *J Clin Psychiatry* 2003; 64:506–515
9. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet* 2012; 380:2163–2169
10. Sidor MM, Macqueen GM: Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. *J Clin Psychiatry* 2011; 72:156–167
11. Sienaert P, Lambrichts L, Dols A, De Fruyt J: Evidence-based treatment strategies for treatment-resistant bipolar depression: a systematic review. *Bipolar Disord* 2013; 15:61–69
12. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. *Arch Gen Psychiatry* 2003; 60:1079–1088
13. Sanford M, Keating GM: Quetiapine: a review of its use in the management of bipolar depression. *CNS Drugs* 2012; 26:435–460
14. Tohen M, McDonnell DP, Case M, Kanba S, Ha K, Fang YR, Katagiri H, Gomez JC: Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression. *Br J Psychiatry* 2012; 201:376–382
15. Thase ME, Jonas A, Khan A, Bowden CL, Wu X, McQuade RD, Carson WH, Marcus RN, Owen R: Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. *J Clin Psychopharmacol* 2008; 28:13–20
16. Lombardo I, Sachs G, Kolluri S, Kremer C, Yang R: Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome? *J Clin Psychopharmacol* 2012; 32:470–478
17. Sachs GS, Ice KS, Chappell PB, Schwartz JH, Gurtovaya O, Vanderburg DG, Kasuba B: Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial. *J Clin Psychiatry* 2011; 72:1413–1422
18. Van Leshout RJ, MacQueen GM: Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review. *Br J Psychiatry* 2010; 196:266–273
19. Ishibashi T, Horisawa T, Tokuda K, Ishiyama T, Ogasa M, Tagashira R, Matsumoto K, Nishikawa H, Ueda Y, Toma S, Oki H, Tanno N, Saji I, Ito A, Ohno Y, Nakamura M: Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT₇) and 5-HT_{1A} receptor activity. *J Pharmacol Exp Ther* 2010; 334:171–181
20. Latuda prescribing information, July 2013. <http://www.latuda.com/LatudaPrescribingInformation.pdf>
21. Hedlund PB: The 5-HT₇ receptor and disorders of the nervous system: an overview. *Psychopharmacology (Berl)* 2009; 206:345–354
22. Cates LN, Roberts AJ, Huitron-Resendiz S, Hedlund PB: Effects of lurasidone in behavioral models of depression: role of the 5-HT₇ receptor subtype. *Neuropharmacology* 2013; 70:211–217
23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janav S, Weiller E, Hergueta T, Baker R, Dunbar GC: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 1998; 59(Suppl 20):22–33, quiz 34–57
24. Sachs GS: Strategies for improving treatment of bipolar disorder: integration of measurement and management. *Acta Psychiatr Scand Suppl* 2004; 422:7–17
25. Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; 134:382–389
26. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. *Psychiatry Res* 1997; 73:159–171
27. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. *Biol Psychiatry* 2003; 54:573–583
28. Hamilton M: The assessment of anxiety states by rating. *Br J Med Psychol* 1959; 32:50–55
29. Sheehan DV: *The Anxiety Disease*. New York, Bantam Books, 1983
30. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. *Psychopharmacol Bull* 1993; 29:321–326
31. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. *Br J Psychiatry* 1978; 133:429–435
32. Chappell P, Feltner DE, Makumi C, Stewart M: Initial validity and reliability data on the Columbia-Suicide Severity Rating Scale. *Am J Psychiatry* 2012; 169:662–663, author reply 663
33. Bech P, Tanghøj P, Andersen HF, Overø K: Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression. *Psychopharmacology (Berl)* 2002; 163:20–25
34. Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y: *Multiple Comparisons and Multiple Tests Using the SAS System*. SAS Institute Inc, 1999
35. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W: Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. *Am J Psychiatry* 2004; 161:2045–2049
36. De Fruyt J, Deschepper E, Audenaert K, Constant E, Floris M, Pitchot W, Sienaert P, Souery D, Claes S: Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis. *J Psychopharmacol* 2012; 26:603–617
37. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* (Epub ahead of print: June 27, 2013; doi: 10.1016/S0140-6736(13)60733-3
38. Vancampfort D, Vansteelandt K, Correll CU, Mitchell AJ, De Hert A, Sienaert P, Probst M, De Hert M: Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. *Am J Psychiatry* 2013; 170:265–274
39. Goldstein BI, Fagiolini A, Houck P, Kupfer DJ: Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. *Bipolar Disord* 2009; 11:657–662